MCL
Clinical trials for MCL explained in plain language.
Never miss a new study
Get alerted when new MCL trials appear
Sign up with your email to follow new studies for MCL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New dosing strategy aims to reduce dangerous side effect in blood cancer treatment
Disease control Recruiting nowThis study tests new ways to give the drug sonrotoclax to adults with chronic lymphocytic leukemia or mantle cell lymphoma. The goal is to find a dosing schedule that lowers the risk of tumor lysis syndrome, a serious side effect. About 258 participants will be enrolled to check …
Matched conditions: MCL
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for aggressive lymphoma: drug cocktail aims to control High-Risk MCL
Disease control Recruiting nowThis phase 2 trial is testing whether adding the drug glofitamab after an initial treatment with acalabrutinib (or zanubrutinib) and rituximab can better control high-risk mantle cell lymphoma (MCL) in people who have not been treated before. The study will enroll 30 participants…
Matched conditions: MCL
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New CAR-T therapy targets BAFF-R to fight resistant lymphoma
Disease control Recruiting nowThis early-phase trial tests a new treatment called BAFF-R CAR-T for people with B-cell lymphoma that has come back or stopped responding to standard therapy. The treatment uses a patient's own immune cells, modified to find and attack cancer cells carrying a protein called BAFF-…
Matched conditions: MCL
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a combination of two drugs, glofitamab and lenalidomide, in people with a fast-growing type of lymphoma (mantle cell lymphoma) that has come back or not responded to treatment, especially after a BTK inhibitor stopped working. About 43 adults will receive the dru…
Matched conditions: MCL
Phase: PHASE2 • Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC